FDA Issues Third Warning Letter to Empower Pharmacy — Targeting the Scale of Its GLP-1 Compounding
September 22–23, 2026. The FDA has issued a warning letter to Empower Pharmacy, the Houston-based compounder that became one of the largest U.S. producers of compounded GLP-1 weight-loss drugs. Endpoints News reports: "The FDA has issued a warning letter to compounder Empower Pharmacy over its GLP-1 weight loss treatments. It's the third warning the Houston-based company has..." received — and per Endpoints' summary, the letter cites "copies of brand-name treatments & sterile drug safety concerns" involving tirzepatide and semaglutide. The Houston Chronicle reports the scale of Empower's GLP-1 production is at the center of the letter.
What it means: this is the FDA's most aggressive enforcement step yet against large-scale GLP-1 compounding since the semaglutide/tirzepatide shortage-era copies proliferated — the third warning letter to a single compounder signals the agency is treating high-volume "compounding" as commercial manufacturing subject to full CGMP enforcement1. It matters for patient safety (sterile-production concerns, unapproved copies of brand-name drugs) and for the branded manufacturers' efforts to shut down the copy market. The full warning letter's specific findings are not yet in hand — worth pulling the FDA posting next cycle.
-
An instance of Sovereign regulatory grace periods collapse the moment active enforcement bureaus levy their first statutory fines. — The shortage-era grace that let compounded GLP-1 copies proliferate collapses into active manufacturing enforcement against the largest compounder. ↩︎